Drugs / [18F] DIHYDRO-TESTOSTERONE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02297386 | Nov 2014 → Aug 2018 | prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00588185 | Feb 2003 → Feb 2027 expected | prostate cancer | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F] Dihydro-Testosterone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00588185 ↗ |
| Known as | FDHT | “The purpose of this study is to test the ability of a new PET scan radiotracer, called FDHT (stands for \[18F\] Dihydro-Testosterone), to better find and monitor prostate cancer.” NCT02297386 ↗1“In the present study we are evaluating fluorinated dihydrotestosterone (FDHT) in addition to FDG.” NCT00588185 ↗ |
| Modality | Diagnostic / imaging agent | “new PET scan radiotracer” NCT02297386 ↗ |
| Target | AR | “FDHT is targeted to the AR” NCT00588185 ↗ |